Natangelo et al. summarized the common adverse effects observed during concurrent T-DM1 and radiotherapy treatment for HER-2-positive breast cancer, including cardiotoxicity, pulmonary toxicity, dermatologic toxicity, bone marrow suppression, and brain injury [25]. Here, ERBB2 is linked to breast carcinoma.